CervoMed Inc. (CRVO) Investor Relations Documents

CervoMed Inc. (CRVO) investor relations documents from the company's IR site: 1 presentation, 18 press releases; latest deck 2026-08-10. Read in-app with summaries. First-party data.

CervoMed Corporate Presentation: CervoMed's neflamapimod shows proof-of-concept efficacy in DLB patients, with a planned Phase 3 trial targeting a $5B+ market.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-10PresentationCervoMed Corporate Presentation
2026-08-10Press releaseCervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
2026-08-05Press releaseCervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program a
2026-08-04Press releaseCervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pat
2026-07-14Press releaseCervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dem
2026-07-09Press releaseCervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive A
2026-07-06Press releaseCervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Associ
2026-06-22Press releaseCervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq R
2026-06-18Press releaseCervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
2026-06-18Press releaseCervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
2026-06-12Press releaseCervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
2026-06-10Press releaseCervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Ph
2026-04-07Press releaseCervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Deme
2026-03-19Press releaseCervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in D
2026-03-17Press releaseCervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
2026-03-12Press releaseCervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference
2026-03-05Press releaseCervoMed to Participate in Upcoming Investor Conferences
2026-03-04Press releaseCervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with
2026-02-18Press releaseCervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for

CRVO overview · CRVO earnings · CRVO financials · CRVO KPIs · CRVO ownership · CRVO peers · CRVO filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.